RecruitingNot ApplicableNCT03954171

Platino-resistance in Ovarian Cancer

Sponsor

Institut Claudius Regaud

Enrollment

600 participants

Start Date

Mar 6, 2020

Study Type

INTERVENTIONAL

Conditions

Epithelial Ovarian Cancer

Summary

Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. A prospective database and an associated biological collection will be performed during 5 years: * For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study). Study participation of each patient will be 5 years.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting biological samples (blood and tissue) from women with newly diagnosed ovarian cancer — before treatment starts — to identify factors that predict whether the cancer will become resistant to platinum-based chemotherapy, the most common first-line treatment for ovarian cancer. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with epithelial ovarian cancer (the most common type) at any stage - You have not yet started surgery or chemotherapy (neoadjuvant treatment before surgery is allowed) - You are scheduled to receive platinum-based chemotherapy - You are enrolled in the French social security system **You may NOT be eligible if...** - You have already had surgery to remove the tumor - You have had prior chemotherapy for this cancer - You are not a candidate for platinum-based treatment - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPatients treated with platinum based-chemotherapy

Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice): * before treatment initiation (blood sample), * during hospitalisation for surgery (blood sample), * during follow-up consultations (blood sample). If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.